The Sputnik V vaccine’s efficacy is confirmed at 91.4% based on data analysis of the final control point of clinical trials
· The efficacy of the Sputnik V vaccine is 91.4%, based on the final control point analysis of data obtained 21 days after administering the first dose.
Ø Calculation was based on the analysis of data of volunteers (n = 22 714) who received both the first and second doses of the Sputnik V vaccine or placebo at the third and final control point of 78 confirmed cases in accordance with the Phase III clinical trials protocol.
Ø The advance to the third and final statistically significant representative control point allowed for the final proof of the efficacy of the vaccine of over 90%.
Ø The Sputnik V vaccine efficacy against severe cases of coronavirus was 100%. Among the confirmed cases of coronavirus infection, 20 severe cases were recorded in the placebo group, while no severe cases were recorded in the vaccine group.
· High efficacy rate of the vaccine above 90% was confirmed at each of the three control points of clinical trials. According to the protocol of Phase III clinical trials of the Sputnik V vaccine, its interim efficacy is calculated at three statistically significant representative control points - upon reaching 20, 39 and 78 cases of novel coronavirus infection among volunteers both in the placebo group and in the group that received the vaccine.
Ø In the first control point of data analyses (20 cases) the vaccine demonstrated 92% calculated efficacy rate, at the second point (39 cases) efficacy rate was 91.4%.
· The research data will be published by the Gamaleya Center team in one of the leading international peer-reviewed medical journals.
· Based on the data obtained at the third control point the Gamaleya Center will create a report that will be used to submit for accelerated registration of the Sputnik V vaccine in various countries.
· The uniqueness of the Russian vaccine lies in the use of two different human adenoviral vectors as a delivery mechanism of the outer coat genetic material of coronavirus to human body. This approach provides for creation of a stronger and long-term immunity as compared to vaccines, using one and the same component for both doses.
· By now over 26,000 volunteers have been vaccinated as part of double-blind, randomized, placebo-controlled Phase III post-registration clinical trials of Sputnik V in Russia.
· No unexpected adverse events were identified as part of the research. Health conditions of the participants will be monitored for at least 6 months after receiving the first immunization.
· Phase III clinical trials of the Sputnik V vaccine is conducted in compliance with the best international standards and practices. During the clinical trials, the safety of the vaccine is constantly being monitored; information is analyzed by the Independent Monitoring Committee comprising leading scientists.
· The Sputnik V vaccine is based on a proven and well-studied platform of human adenoviral vectors. This platform has a number of key advantages including safety, efficacy and no negative long-term effects, which have been proven by more than 250 clinical studies over two decades (while the history of use of human adenoviruses in vaccines started in 1953). Over 100,000 people have been vaccinated with approved and registered vaccines based on human adenoviral vectors.
Moscow, December 14, 2020 – The National Research Center for Epidemiology and Microbiology named after N.F. Gamaleya of the Ministry of Health of the Russian Federation (Gamaleya Center) and the Russian Direct Investment Fund (RDIF, Russia’s sovereign wealth fund), announce the efficacy of over 90% of the Russian Sputnik V vaccine as demonstrated by the final control point data analysis of the largest double-blind, randomized, placebo-controlled Phase III post-registration clinical trials of the Sputnik V vaccine against novel coronavirus infection in Russia’s history. Sputnik V is the world’s first registered vaccine against coronavirus based on a well-studied human adenoviral vectors platform.
Evaluation of efficacy was carried out among volunteers (n = 22 714) 21 days after receiving the first dose of the vaccine or placebo upon reaching the third and final statistically significant representative control point of the trial in compliance with the Phase III clinical trial protocol of the Sputnik V vaccine. The data analysis at the final control point of the trials demonstrated a 91.4% efficacy rate. According to the protocol the advance to the final control point allowed for the final proof of the efficacy of the vaccine of over 90%.
The analysis of the Sputnik V vaccine efficacy at the final control point was carried out on the basis of 78 confirmed cases identified in the placebo group (62 cases) and in the vaccine group (16 cases). The ratio of the placebo group to the vaccinated group is 1 to 3.
|
Efficacy calculation based on the number of cases |
||||
|
|
3:1 |
Number of cases |
Rate |
Efficacy |
|
Vaccine |
17032 |
16 |
0.094% |
91.4% |
|
Placebo |
5682 |
62 |
1.09% |
|
***
The vaccine demonstrated 100% efficacy against severe coronavirus cases. There were 20 severe cases of coronavirus infection among confirmed cases in the placebo group and no severe cases in the vaccine group.
According to the protocol of Phase III clinical trials of the Sputnik V vaccine, its interim efficacy is calculated at three statistically significant representative control points - upon reaching 20, 39 and 78 cases of novel coronavirus infection among volunteers both in the placebo group and in the group that received the vaccine. High efficacy rate of the vaccine above 90% was confirmed at each of the three control points of clinical trials – the calculated efficacy rate of the Sputnik V vaccine at the first control point (20 cases) was 92% and 91.4% at the second point (39 cases).
Based on the data obtained at the third control point the Gamaleya Center will create a report that will be used to submit for accelerated registration of the Sputnik V vaccine in various countries.
The research data will be published by the Gamaleya Center team in one of the leading international peer-reviewed medical journals.
***
As of December 14 more than 26,000 volunteers were vaccinated at 29 medical centers in Russia as part of the ongoing clinical trials. Currently Phase III clinical trials are approved and are ongoing in Belarus, the UAE, Venezuela and other countries, as well as Phase II-III in India.
As of December 14, no unexpected adverse events were identified as part of the research. Some of those vaccinated had short-term minor adverse events such as pain at the injection point and flu-like symptoms including fever, weakness, fatigue, and headache.
During the clinical trials, the safety of the vaccine is constantly being monitored; information is analyzed by the Independent Monitoring Committee comprising leading Russian scientists. Collection, quality control and data processing is conducted in line with ICH GCP standards and involves the active participation of Moscow’s Health Department and Crocus Medical, the contract research organization (CRO).
Sputnik V has a unique set of parameters making it one of the most competitive vaccines globally. The efficacy rate is over 90% and the vaccine is based on a safe and proven platform of human adenoviral vectors. Cost of one dose is less than $10 for international markets while the production of the lyophilized (dry) form of the vaccine, which is stored at a temperature of +2 to +8 degrees Celsius, enables easier distribution of the vaccine in international markets.
Mikhail Murashko, Minister of Health of the Russian Federation, said:
“The new data on efficacy of the Gamaleya Center vaccine is extremely encouraging. Today it has become obvious to everyone that the end of the pandemic is possible only after the mass vaccination of the entire global population. In this regard, ensuring equal access to effective and safe vaccines, including the Sputnik V vaccine, for people in every country should be the goal of foreign regulatory bodies and international organizations.”
Alexander Gintsburg, Gamaleya Center Director, said:
“Results the Sputnik V vaccine has demonstrated during the Phase III clinical trials support our confidence in its high efficacy and complete safety for health. This is especially important when it comes to the beginning of large-scale vaccination of the population. I believe we will be able to vaccinate most of the population in Russia in 2021 thereby significantly reducing the scale of pandemic and creating a strong long-term immunity to coronavirus infection in a significant part of Russia's population.”
Denis Logunov, Gamaleya Center Deputy Director, commented:
“The Sputnik V vaccine has proven to be highly effective, as demonstrated by the data from the initial stages of the study that were announced earlier. It is important that at each stage the calculated vaccine efficiency rate exceeded 90%. We will definitely share the results achieved with the scientific community and will be happy to discuss them with all interested colleagues. Monitoring of participants’ condition will continue.”
Kirill Dmitriev, CEO, Russian Direct Investment Fund, said:
“The data analysis at the third and final control point of the Sputnik V vaccine clinical trials confirmed the efficacy of the vaccine of over 90%. Clinical trials have proven this in the three consecutive statistically important points described in trials protocol. The data obtained will lay a basis for a report that will be used to submit applications for accelerated registration of the Russian vaccine in other countries. We also see high interest from international pharmaceutical companies in the Gamaleya Center vaccine, since the use of Sputnik V components in combination with other vaccines can significantly increase their efficacy.”
***
The safety of vaccines based on human adenoviruses has been confirmed in more than 75 international publications and more than 250 clinical trials conducted during the past two decades - while the history of use of human adenoviruses in vaccine development started in 1953. Adenovirus vectors are genetically modified viruses of the regular flu that cannot reproduce in a human body. When the Sputnik V vaccine is used, the coronavirus itself does not enter the body as the vaccine only contains genetic information about part of its outer protein coat, the so called "spikes" forming its crown. This completely eliminates the possibility of getting infected as a result of vaccination while also causing the body's stable immune response.
On September 4, The Lancet, one of world’s leading medical journals, published a research paper on the results of Phase I and Phase II clinical trials of the vaccine that showed no serious adverse events and an effective immune response of those vaccinated.
Requests for vaccination of more than 1.2 billion people (2.4 billion doses) with the Sputnik V vaccine came from more than 50 countries. The vaccine supplies for the global market will be produced by RDIF’s international partners in India, Brazil, China, South Korea and other countries.
On August 11, the Sputnik V vaccine developed by the Gamaleya Center was registered by Russia’s Health Ministry and became the world’s first registered vaccine against COVID-19. Detailed information on the Sputnik V vaccine, its human adenoviral vectors technological platform, and other details are available at sputnikvaccine.com
Be the first to learn about Sputnik V on social networks:
***
Russian Direct Investment Fund (RDIF) is Russia's sovereign wealth fund established in 2011 to make equity co-investments, primarily in Russia, alongside reputable international financial and strategic investors. RDIF acts as a catalyst for direct investment in the Russian economy. RDIF’s management company is based in Moscow. Currently, RDIF has experience of the successful joint implementation of more than 80 projects with foreign partners totaling more than RUB1.9 trillion and covering 95% of the regions of the Russian Federation. RDIF portfolio companies employ more than 800,000 people and generate revenues which equate to more than 6% of Russia’s GDP. RDIF has established joint strategic partnerships with leading international co-investors from more than 18 countries that total more than $40 bn. Further information can be found at rdif.ru
The Gamaleya National Research Center for Epidemiology and Microbiology of the Ministry of Health of the Russian Federation is one of the oldest research centers in Russia, which celebrated its 100th anniversary in 1991. The main focus of the center's research is the fundamental problems in epidemiology, medical and molecular microbiology, and infectious immunology. More information can be found at gamaleya.org
For additional information contact:
Arseniy Palagin Andrew Leach / Maria Shiryaevskaya
Russian Direct Investment Fund Hudson Sandler
Press Secretary Tel: +44 (0) 20 7796 4133
Tel: +7 495 644 34 14, ext. 2395
Mobile: +7 916 110 31 41
E-mail: arseniy.palagin@rdif.ru
Editor Details
-
Company:
- Russian Direct Investment Fund
-
Name:
- Russian Direct Investment Fund
